SG11202110590PA - Inhibitors of aldose reductase - Google Patents

Inhibitors of aldose reductase

Info

Publication number
SG11202110590PA
SG11202110590PA SG11202110590PA SG11202110590PA SG11202110590PA SG 11202110590P A SG11202110590P A SG 11202110590PA SG 11202110590P A SG11202110590P A SG 11202110590PA SG 11202110590P A SG11202110590P A SG 11202110590PA SG 11202110590P A SG11202110590P A SG 11202110590PA
Authority
SG
Singapore
Prior art keywords
inhibitors
aldose reductase
aldose
reductase
Prior art date
Application number
SG11202110590PA
Other languages
English (en)
Inventor
Andrew Wasmuth
Original Assignee
Applied Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Therapeutics Inc filed Critical Applied Therapeutics Inc
Publication of SG11202110590PA publication Critical patent/SG11202110590PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11202110590PA 2019-04-01 2020-03-31 Inhibitors of aldose reductase SG11202110590PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962827362P 2019-04-01 2019-04-01
US201962928735P 2019-10-31 2019-10-31
PCT/US2020/025928 WO2020205846A1 (en) 2019-04-01 2020-03-31 Inhibitors of aldose reductase

Publications (1)

Publication Number Publication Date
SG11202110590PA true SG11202110590PA (en) 2021-10-28

Family

ID=70416582

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110590PA SG11202110590PA (en) 2019-04-01 2020-03-31 Inhibitors of aldose reductase

Country Status (12)

Country Link
US (1) US20220017535A1 (zh)
EP (1) EP3947391A1 (zh)
JP (1) JP2022519944A (zh)
KR (1) KR20220003529A (zh)
CN (1) CN113840825A (zh)
AU (1) AU2020254610A1 (zh)
BR (1) BR112021019596A2 (zh)
CA (1) CA3132136A1 (zh)
IL (1) IL286832A (zh)
MX (1) MX2021011858A (zh)
SG (1) SG11202110590PA (zh)
WO (1) WO2020205846A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111065392A (zh) 2017-07-28 2020-04-24 应用治疗公司 用于治疗半乳糖血症的组合物和方法
CA3153108A1 (en) * 2019-10-08 2021-04-15 Riccardo Perfetti Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
WO1989006651A1 (en) * 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
JPH11512095A (ja) 1995-08-28 1999-10-19 アメリカン・ホーム・プロダクツ・コーポレイション アルドース還元酵素阻害薬および抗高血糖症薬としてのフェノキシ酢酸
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
AU2003243603A1 (en) 2002-06-13 2003-12-31 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
KR20090084439A (ko) 2008-02-01 2009-08-05 부경대학교 산학협력단 고삼 추출물 또는 이로부터 분리한 프레닐레이티드플라보노이드 화합물을 함유한 당뇨성 합병증의 예방 또는치료용 조성물
DK2326632T3 (en) 2008-09-06 2017-09-18 Bionevia Pharmaceuticals Inc New choline crystal of epalrestate
CN105732640B (zh) * 2010-07-16 2019-01-08 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其用途
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
KR101695166B1 (ko) 2010-11-23 2017-01-12 대한민국 돌나물 추출물을 포함하는 당뇨병 합병증의 예방 또는 치료용 조성물
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
EP3202400A4 (en) 2015-04-30 2018-06-13 Institute Of Microbiology, Chinese Academy Of Sciences Aromatic farnesyl compound and application thereof
JP6500992B2 (ja) 2015-09-01 2019-04-17 株式会社村田製作所 コイル内蔵部品
MX2018016122A (es) * 2016-06-21 2019-08-01 Univ Columbia Inhibidores de aldosa reductasa y metodos de uso.
CN111065392A (zh) * 2017-07-28 2020-04-24 应用治疗公司 用于治疗半乳糖血症的组合物和方法

Also Published As

Publication number Publication date
EP3947391A1 (en) 2022-02-09
KR20220003529A (ko) 2022-01-10
MX2021011858A (es) 2022-01-18
US20220017535A1 (en) 2022-01-20
CA3132136A1 (en) 2020-10-08
CN113840825A (zh) 2021-12-24
JP2022519944A (ja) 2022-03-25
BR112021019596A2 (pt) 2021-11-30
IL286832A (en) 2021-10-31
AU2020254610A1 (en) 2021-11-18
WO2020205846A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
IL277127A (en) Use of PCSK9 monitoring to reduce cardiovascular risk
EP4069212A4 (en) HIF-2 ALPHA INHIBITORS
IL289879A (en) Solid forms of hpk1 inhibitor
EP3801503A4 (en) INHIBITORS OF SARM1
EP3856176A4 (en) VAP-1 INHIBITORS
EP3638229A4 (en) IMIDAZOLE INHIBITORS FROM ALK2-KINASE
IL283809A (en) Aldose reductase inhibitors and methods of using them
EP3906029A4 (en) INHIBITORS OF MENIN-MLL INTERACTION
EP3609882A4 (en) HETEROCYCLIC INHIBITORS OF PCSK9
EP3804758A4 (en) BIOMARKER FOR ASSESSING THE EFFECTIVENESS OF AN IMMUNE CHECKPOINT INHIBITOR
EP3982949A4 (en) MRSA1 INHIBITORS
EP3980011A4 (en) MRSA1 INHIBITORS
EP3402521A4 (en) INHIBITION OF ALLERGIC REACTION USING AN IL-33 INHIBITOR
EP3801499A4 (en) INHIBITORS OF SARM1
SG11202109781QA (en) Uses of phosphodiesterase inhibitors
IL286832A (en) Aldose reductase inhibitors
EP3999498A4 (en) CYCLIN-DEPENDENT KINASE INHIBITORS
EP3801500A4 (en) INHIBITORS OF SARM1
EP3856194A4 (en) VAP-1 INHIBITORS
EP3870181A4 (en) CRYSTAL FORMS OF AN ALK2 INHIBITOR
EP3801525A4 (en) PROLYL-ARNT-SYNTHETASE INHIBITORS
EP4055158A4 (en) BROAD-SPECTRUM CRISPR-CAS9 INHIBITORS
IL274015A (en) Inhibitors of tyrosine-kinases from the mutant Agfer family
EP3484888A4 (en) SOLID FORMS OF A TTK INHIBITOR
IL291368A (en) Inhibits expression of methadherin